Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levocloperastine is a non-opioid antitussive agent that functions through a dual mechanism of action, affecting both the central nervous system and peripheral receptors. It acts centrally on the bulbar cough center, primarily by exhibiting high-affinity binding as an agonist to sigma-1 (σ1) receptors and by potently inhibiting G-protein-coupled inwardly-rectifying potassium (GIRK) channels within key nuclei of the medulla oblongata, such as the nucleus tractus solitarius (NTS). Additionally, it exerts peripheral effects on the tracheobronchial tree. This combined action suppresses the cough reflex, making it effective for the symptomatic relief of dry cough. Levocloperastine is the levorotatory isomer of cloperastine and is administered orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levocloperastine.